Sign In
Buy ENTA
$13.37
+0.710 (+5.61%)
At Close: Jun 22, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
11:00am, Thursday, 15'th May 2025
The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
06:10pm, Monday, 12'th May 2025
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $1.47 per share a year ago.
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
07:00am, Tuesday, 08'th Apr 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025.
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
01:06pm, Friday, 14'th Feb 2025
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
06:11pm, Monday, 10'th Feb 2025
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
04:01pm, Monday, 10'th Feb 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
07:00am, Tuesday, 24'th Dec 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indication
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?
10:46am, Monday, 23'rd Dec 2024
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the nea
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
06:11pm, Monday, 25'th Nov 2024
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.33 per share a year ago.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
04:01pm, Monday, 25'th Nov 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
08:56am, Wednesday, 02'nd Oct 2024
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the nea
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV.
